Suppr超能文献

患者对佛蒙特州中心辐射式系统中使用药物治疗阿片类药物使用障碍(MOUD)的治疗感受。

Patient perceptions of treatment with medication treatment for opioid use disorder (MOUD) in the Vermont hub-and-spoke system.

机构信息

Vermont Center for Behavior and Health, Lerner School of Medicine, University of Vermont, 1 South Prospect Street, Burlington, VT 05733, USA; Integrated Substance Abuse Programs, Geffen School of Medicine, University of California at Los Angeles, 11075 Santa Monica Blvd., Ste. 200, Los Angeles, CA 90025, USA.

GreenField Health, Portland, OR, USA; School of Medicine, Department of Psychiatry, Oregon Health and Science University, 3181 SW Sam Jackson Park Road, CB669, Portland, OR 97239, USA.

出版信息

Prev Med. 2019 Nov;128:105785. doi: 10.1016/j.ypmed.2019.105785. Epub 2019 Jul 27.

Abstract

In 2013, Vermont leaders implemented the "hub-and-spoke" (H & S) system to increase access to medication treatment for opioid use disorder (MOUD). "Hubs" are licensed specialty opioid treatment programs (OTPs) with the authority to dispense buprenorphine/naloxone and methadone. "Spokes" are primary care practices that provide office-based opioid treatment, primarily with buprenorphine/naloxone. This report describes the qualitative component of an evaluation of the H&S system, conducted in 2016. The qualitative data collection assessed patient perspectives about the positive and negative aspects of treatment in the H & S system. The data collected included 80 responses to five open-ended questions and 24 in-depth interviews. Five open-ended questions were completed with hub (n = 40) and spoke (n = 40) participants. In-depth qualitative interviews were conducted with different hub (n =12) and spoke (n =12) participants. Findings from both data collection approaches suggest positive perceptions about treatment overall by patients treated in both settings. Participants treated in spokes reported a positive treatment environment, minimal stigma, and few obstacles to treatment and a strong positive relationship with their prescriber. Hub patients valued the MOUD and expressed gratitude for having access to MOUD, but reported the treatment environment was somewhat challenging, with long lines and drug talk in the clinic, high staff turnover and "cookie cutter" treatment. There appear to be some differences in patient perceptions of MOUD treatment between patients treated in primary care settings and specialized OTP settings.

摘要

2013 年,佛蒙特州的领导人实施了“枢纽-辐射”(H & S)系统,以增加阿片类药物使用障碍(MOUD)药物治疗的可及性。“枢纽”是具有分发丁丙诺啡/纳洛酮和美沙酮权限的持牌专科阿片类药物治疗计划(OTP)。“辐射”是提供基于办公室的阿片类药物治疗的初级保健实践,主要使用丁丙诺啡/纳洛酮。本报告描述了 2016 年对 H & S 系统进行的评估的定性部分。定性数据收集评估了患者对 H & S 系统中治疗的积极和消极方面的看法。收集的数据包括对五个开放式问题的 80 个回复和 24 次深度访谈。枢纽(n = 40)和辐射(n = 40)参与者完成了五个开放式问题。对不同的枢纽(n = 12)和辐射(n = 12)参与者进行了深入的定性访谈。两种数据收集方法的结果均表明,接受治疗的患者对治疗总体持积极态度。在辐射环境中接受治疗的参与者报告说,治疗环境良好,耻辱感极小,治疗障碍很少,与他们的处方者关系非常积极。枢纽患者重视 MOUD,并对获得 MOUD 表示感谢,但报告说治疗环境有些挑战,诊所里有长队和毒品谈话、高员工流动率和“一刀切”的治疗。在接受初级保健环境和专门的 OTP 环境治疗的患者中,患者对 MOUD 治疗的看法似乎存在一些差异。

相似文献

2
Preliminary results of the evaluation of the California Hub and Spoke Program.
J Subst Abuse Treat. 2020 Jan;108:26-32. doi: 10.1016/j.jsat.2019.07.014. Epub 2019 Aug 1.
3
System-level factors shaping the implementation of "hub and spoke" systems to expand MOUD in rural areas.
Subst Abus. 2021;42(4):716-725. doi: 10.1080/08897077.2020.1846149. Epub 2020 Dec 7.
4
Assessing perceptions about medications for opioid use disorder and Naloxone on Twitter.
J Addict Dis. 2021 Jan-Mar;39(1):37-45. doi: 10.1080/10550887.2020.1811456. Epub 2020 Aug 24.
5
Perceptions around medications for opioid use disorder among a diverse sample of U.S. adults.
J Subst Use Addict Treat. 2024 Aug;163:209361. doi: 10.1016/j.josat.2024.209361. Epub 2024 May 3.
6
The Washington State Hub and Spoke Model to increase access to medication treatment for opioid use disorders.
J Subst Abuse Treat. 2020 Jan;108:33-39. doi: 10.1016/j.jsat.2019.07.007. Epub 2019 Jul 19.
8
Readiness and recovery: Transferring between methadone and buprenorphine/naloxone for the treatment of opioid use disorder.
Int J Ment Health Nurs. 2019 Feb;28(1):226-236. doi: 10.1111/inm.12523. Epub 2018 Jul 18.
10
Prescribing and Acceptance of Medications for Opioid Use Disorder in VA Primary Care: Veteran and Provider Perspectives.
J Gen Intern Med. 2024 Jul;39(9):1690-1697. doi: 10.1007/s11606-024-08703-z. Epub 2024 Apr 8.

引用本文的文献

1
Patient centered medication treatment for opioid use disorder in rural Vermont: a qualitative study.
Addict Sci Clin Pract. 2025 Jan 14;20(1):3. doi: 10.1186/s13722-024-00529-8.
2
Content analysis of perceptions of combined pharmacobehavioral treatment for American Indian people with opioid use disorder.
Psychol Addict Behav. 2025 Feb;39(1):1-13. doi: 10.1037/adb0001037. Epub 2025 Jan 9.
4
Exploring the Lived Experiences of Medication for Opioid use Disorder Treatment: A Qualitative Study among a Crowdsourced Convenience Sample.
Community Ment Health J. 2025 Apr;61(3):411-419. doi: 10.1007/s10597-024-01345-9. Epub 2024 Sep 5.
5
Expanding access to medication treatment for opioid use disorders: Findings from the Washington State hub and spoke effort.
Drug Alcohol Depend. 2024 Mar 1;256:111125. doi: 10.1016/j.drugalcdep.2024.111125. Epub 2024 Feb 14.
6
Understanding Regional Patterns of Overdose Deaths Related to Opioids and Psychostimulants.
Subst Use Misuse. 2024;59(4):558-566. doi: 10.1080/10826084.2023.2287220. Epub 2024 Feb 8.
7
Patient and Provider Perspectives on Processes of Engagement in Outpatient Treatment for Opioid Use Disorder: A Scoping Review.
Community Ment Health J. 2024 Feb;60(2):330-339. doi: 10.1007/s10597-023-01175-1. Epub 2023 Sep 5.
8
Examining the Primary Care Experience of Patients With Opioid Use Disorder: A Qualitative Study.
J Addict Med. 2023;17(4):401-406. doi: 10.1097/ADM.0000000000001140. Epub 2023 Jan 25.
9
Implementation of a hospital-based intervention for MOUD initiation and referral to a Bridge Clinic for opioid use disorder.
J Subst Use Addict Treat. 2023 Mar;146:208961. doi: 10.1016/j.josat.2023.208961. Epub 2023 Jan 24.
10
Challenges of methadone maintenance treatment decentralisation from Vietnamese primary care providers' perspectives.
Drug Alcohol Rev. 2023 May;42(4):803-814. doi: 10.1111/dar.13613. Epub 2023 Feb 27.

本文引用的文献

1
Assessment of medication for opioid use disorder as delivered within the Vermont hub and spoke system.
J Subst Abuse Treat. 2019 Feb;97:84-90. doi: 10.1016/j.jsat.2018.11.003. Epub 2018 Nov 19.
3
Vermont Hub-and-Spoke Model of Care for Opioid Use Disorder: Development, Implementation, and Impact.
J Addict Med. 2017 Jul/Aug;11(4):286-292. doi: 10.1097/ADM.0000000000000310.
4
Systemic and individual factors in the buprenorphine treatment-seeking process: a qualitative study.
Subst Abuse Treat Prev Policy. 2017 Jan 11;12(1):3. doi: 10.1186/s13011-016-0085-y.
7
Vermont responds to its opioid crisis.
Prev Med. 2015 Nov;80:10-1. doi: 10.1016/j.ypmed.2015.04.002. Epub 2015 Apr 11.
8
Patients' Reasons for Choosing Office-based Buprenorphine: Preference for Patient-Centered Care.
J Addict Med. 2010 Dec;4(4):204-10. doi: 10.1097/ADM.0b013e3181cc9610.
9
Substance use and the quality of patient-provider communication in HIV clinics.
AIDS Behav. 2011 May;15(4):832-41. doi: 10.1007/s10461-010-9779-8.
10
Patient adherence and medical treatment outcomes: a meta-analysis.
Med Care. 2002 Sep;40(9):794-811. doi: 10.1097/00005650-200209000-00009.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验